AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 10489654 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 134
Study 9173439 — intervention group
Group type: EXPERIMENTAL
Intervention: Phagocytic activity of blood platelets
Number of subjects: 35
Study 9173439 — intervention group
Group type: EXPERIMENTAL
Intervention: Blood platelets count
Number of subjects: 35
Study 1750018 — intervention group
Group type: EXPERIMENTAL
Intervention: Nebulised amiloride (1 mg in 3 ml saline) via System 22 nebuliser
Number of subjects: 8
Study 1750018 — intervention group
Group type: EXPERIMENTAL
Intervention: Nebulised amiloride (1 mg in 3 ml saline) via Fisoneb nebuliser
Number of subjects: 8
Study 1750018 — intervention group
Group type: EXPERIMENTAL
Intervention: Nebulised amiloride via Fisoneb nebuliser
Number of subjects: 8
Study 1750018 — intervention group
Group type: EXPERIMENTAL
Intervention: Nebulised amiloride
Number of subjects: 8
Study 6311242 — intervention group
Group type: EXPERIMENTAL
Intervention: Pectin (12 g/d)
Number of subjects: 0
Study 6311242 — intervention group
Group type: EXPERIMENTAL
Intervention: Cellulose (15 g/d)
Number of subjects: 0
Study 6311242 — intervention group
Group type: EXPERIMENTAL
Intervention: Lignin (12 g/d)
Number of subjects: 0
Study 29925775 — intervention group
Group type: EXPERIMENTAL
Intervention: Inulin supplement (10 g/day)
Number of subjects: 18
Study 29925775 — intervention group
Group type: COMPARATOR
Intervention: Maltodextrin placebo
Number of subjects: 18
Study 27152906 — intervention group
Group type: EXPERIMENTAL
Intervention: Low status group
Number of subjects: 0
Study 27152906 — intervention group
Group type: COMPARATOR
Intervention: High status group
Number of subjects: 0
Study 24886443 — intervention group
Group type: EXPERIMENTAL
Intervention: PLA1A2 polymorphism in prediabetic subjects with HbA1c > 5.5% (37 mmol/mol)
Number of subjects: 4028
Study 24886443 — intervention group
Group type: EXPERIMENTAL
Intervention: PLA1A2 polymorphism in diabetic patients
Number of subjects: 4028
Study 24886443 — intervention group
Group type: EXPERIMENTAL
Intervention: PLA1A2 polymorphism in general population
Number of subjects: 4028
Study 24886443 — intervention group
Group type: EXPERIMENTAL
Intervention: HbA1c levels in non-diabetic persons
Number of subjects: 4028
Study 24886443 — intervention group
Group type: EXPERIMENTAL
Intervention: PLA1A2 polymorphism in participants with HbA1c ranging from 5.5% (37 mmol/mol) to 6.5% (48 mmol/mol)
Number of subjects: 4028
Study 22492372 — intervention group
Group type: EXPERIMENTAL
Intervention: Methionine intake of 3 to 59 mg kg(‐1) d(‐1)
Number of subjects: 33
Study 22492372 — intervention group
Group type: COMPARATOR
Intervention: Current recommended methionine intake of 28 mg kg(‐1) d(‐1)
Number of subjects: 33
Study 22492372 — intervention group
Group type: COMPARATOR
Intervention: Infant formulas providing methionine intake of 49-80 mg kg(‐1) d(‐1)
Number of subjects: 33
Study 20307216 — intervention group
Group type: EXPERIMENTAL
Intervention: LUMIGAN (bimatoprost ophthalmic solution, 0.03%)
Number of subjects: 12
Study 20307216 — intervention group
Group type: EXPERIMENTAL
Intervention: TRAVATAN (travoprost ophthalmic solution, 0.004%)
Number of subjects: 12
Study 18508828 — intervention group
Group type: EXPERIMENTAL
Intervention: Mometasone furoate (MF), 400 microg once daily
Number of subjects: 144
Study 18508828 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 144
Study 16996600 — intervention group
Group type: EXPERIMENTAL
Intervention: PDT followed by approximately 11 mg IVTA
Number of subjects: 61
Study 16996600 — intervention group
Group type: COMPARATOR
Intervention: PDT
Number of subjects: 61
Study 11855904 — intervention group
Group type: EXPERIMENTAL
Intervention: Implicit power motivation, low activity inhibition
Number of subjects: 66
Study 11855904 — intervention group
Group type: EXPERIMENTAL
Intervention: Testosterone increases, low activity inhibition
Number of subjects: 66
Study 11855904 — intervention group
Group type: EXPERIMENTAL
Intervention: Testosterone increases in winners, low activity inhibition
Number of subjects: 66
Study 11855904 — intervention group
Group type: COMPARATOR
Intervention: Participants high in activity inhibition
Number of subjects: 66
Study 10442963 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol (2.5 mg x kg(‐1) with 1 microg x kg(‐1) fentanyl)
Number of subjects: 120
Study 10442963 — intervention group
Group type: EXPERIMENTAL
Intervention: Thiopental (5 mg x kg(‐1) with 1 microg x kg(‐1) fentanyl)
Number of subjects: 120
Study 10442963 — intervention group
Group type: EXPERIMENTAL
Intervention: Thiopental (5 mg x kg(‐1) with 1 microg x kg(‐1) fentanyl) and atracurium (0.05 mg x kg(‐1))
Number of subjects: 120
Study 10442963 — intervention group
Group type: EXPERIMENTAL
Intervention: Thiopental (5 mg x kg(‐1) with 1 microg x kg(‐1) fentanyl) and atracurium (0.1 mg x kg(‐1))
Number of subjects: 120
Study 8685641 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefuroxime (1.5 g, i.v. every 8 h for 2 days)
Number of subjects: 1079
Study 8685641 — intervention group
Group type: COMPARATOR
Intervention: No further antibiotics
Number of subjects: 1079
Study 8685641 — intervention group
Group type: COMPARATOR
Intervention: Metronidazole (1 g i.v. at induction and 12 h postoperatively)
Number of subjects: 1079
Study 1971831 — intervention group
Group type: EXPERIMENTAL
Intervention: Estazolam 2 mg
Number of subjects: 229
Study 1971831 — intervention group
Group type: EXPERIMENTAL
Intervention: Flurazepam 30 mg
Number of subjects: 229
Study 1971831 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 229
Study 1971831 — intervention group
Group type: EXPERIMENTAL
Intervention: Flurazepam
Number of subjects: 229
Study 1971831 — intervention group
Group type: EXPERIMENTAL
Intervention: Estazolam
Number of subjects: 229
Study 549782 — intervention group
Group type: EXPERIMENTAL
Intervention: Tienilic acid (TA) 250-750 mg/die
Number of subjects: 30
Study 549782 — intervention group
Group type: COMPARATOR
Intervention: Hydrochlorothiazide (HCT) 50-150 mg/die
Number of subjects: 30
Study 549782 — intervention group
Group type: EXPERIMENTAL
Intervention: Tienilic acid (TA) 250-1000 mg/die in congestive heart failure patients
Number of subjects: 30
Study 31581605 — intervention group
Group type: EXPERIMENTAL
Intervention: Agaricus blazei-based extract AndosanTM
Number of subjects: 60
Study 31581605 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 28030882 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional hydrogel (Omafilcon A)
Number of subjects: 54
Study 28030882 — intervention group
Group type: EXPERIMENTAL
Intervention: Silicone hydrogel (comfilcon A)
Number of subjects: 54
Study 28030882 — intervention group
Group type: COMPARATOR
Intervention: Standard environment (50% RH, 23°C, 930 mb atmospheric pressure)
Number of subjects: 54
Study 28030882 — intervention group
Group type: EXPERIMENTAL
Intervention: Adverse environment (5% RH, localized air flow, 23°C, 750 mb atmospheric pressure)
Number of subjects: 54
Study 28030882 — intervention group
Group type: EXPERIMENTAL
Intervention: Both environments and CL types
Number of subjects: 54
Study 25542821 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg ulipristal acetate
Number of subjects: 451
Study 25542821 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg ulipristal acetate
Number of subjects: 451
Study 23568254 — intervention group
Group type: EXPERIMENTAL
Intervention: PEEK cage
Number of subjects: 80
Study 23568254 — intervention group
Group type: COMPARATOR
Intervention: Titanium cage
Number of subjects: 80
Study 21034680 — intervention group
Group type: EXPERIMENTAL
Intervention: escitalopram
Number of subjects: 133
Study 21034680 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 133
Study 17604885 — intervention group
Group type: EXPERIMENTAL
Intervention: 1% lidocaine with epinephrine
Number of subjects: 96
Study 17604885 — intervention group
Group type: COMPARATOR
Intervention: 1% lidocaine
Number of subjects: 96
Study 17089219 — intervention group
Group type: EXPERIMENTAL
Intervention: Thermal mineral water treatment
Number of subjects: 64
Study 17089219 — intervention group
Group type: COMPARATOR
Intervention: Tap water treatment
Number of subjects: 64
Study 16429619 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 mg SL Apomorphine (APO)
Number of subjects: 24
Study 16429619 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 11304865 — intervention group
Group type: EXPERIMENTAL
Intervention: ThinPrep DFA
Number of subjects: 636
Study 11304865 — intervention group
Group type: COMPARATOR
Intervention: Conventional DFA
Number of subjects: 636
Study 11304865 — intervention group
Group type: EXPERIMENTAL
Intervention: Specimen adequacy
Number of subjects: 636
Study 11304865 — intervention group
Group type: COMPARATOR
Intervention: Chlamydia prevalence
Number of subjects: 636
Study 10998469 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 mg bezafibrate once daily
Number of subjects: 16
Study 10998469 — intervention group
Group type: COMPARATOR
Intervention: Control group (age‐ and sex‐matched subjects)
Number of subjects: 16
Study 8831156 — intervention group
Group type: EXPERIMENTAL
Intervention: Nodding head while encoding positive and negative adjectives
Number of subjects: 0
Study 8831156 — intervention group
Group type: EXPERIMENTAL
Intervention: Shaking head while encoding positive and negative adjectives
Number of subjects: 0
Study 8831156 — intervention group
Group type: EXPERIMENTAL
Intervention: Head movements compatible with words during encoding
Number of subjects: 0
Study 8831156 — intervention group
Group type: COMPARATOR
Intervention: Head movements incompatible with words during encoding
Number of subjects: 0
Study 1596721 — intervention group
Group type: EXPERIMENTAL
Intervention: Nissen total transabdominal fundoplication (360 degrees wrap)
Number of subjects: 52
Study 1596721 — intervention group
Group type: EXPERIMENTAL
Intervention: Lind partial transabdominal fundoplication (300 degrees wrap)
Number of subjects: 52
Study 6697730 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous transcutaneous oxygen (PtcO2) monitoring during the open TcM period
Number of subjects: 20
Study 6697730 — intervention group
Group type: COMPARATOR
Intervention: Control period (PtcO2 data withheld)
Number of subjects: 20
Study 30820940 — intervention group
Group type: EXPERIMENTAL
Intervention: Pentostatin, cyclophosphamide, and rituximab (PCR)
Number of subjects: 83
Study 28328729 — intervention group
Group type: EXPERIMENTAL
Intervention: Two-thumb technique (TTT)
Number of subjects: 37
Study 28328729 — intervention group
Group type: COMPARATOR
Intervention: Two-finger technique (TFT-R23)
Number of subjects: 37
Study 27102319 — intervention group
Group type: EXPERIMENTAL
Intervention: Toothpaste with 250 ppm F
Number of subjects: 32
Study 27102319 — intervention group
Group type: EXPERIMENTAL
Intervention: Toothpaste with 500 ppm F
Number of subjects: 32
Study 27102319 — intervention group
Group type: EXPERIMENTAL
Intervention: Toothpaste with 1250 ppm F
Number of subjects: 32
Study 27102319 — intervention group
Group type: EXPERIMENTAL
Intervention: No rinsing after brushing
Number of subjects: 32
Study 27102319 — intervention group
Group type: COMPARATOR
Intervention: Rinsing after brushing
Number of subjects: 32
Study 24655345 — intervention group
Group type: EXPERIMENTAL
Intervention: PECS training
Number of subjects: 14
Study 24655345 — intervention group
Group type: COMPARATOR
Intervention: Conventional language therapy (CLT)
Number of subjects: 14
Study 22441361 — intervention group
Group type: EXPERIMENTAL
Intervention: S(+)‐ketamine infusion for 60 hours
Number of subjects: 66
Study 22441361 — intervention group
Group type: COMPARATOR
Intervention: Placebo infusion
Number of subjects: 66
Study 20100272 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium hydroxylapatite (CaHA) premixed with 2% lidocaine
Number of subjects: 50
Study 20100272 — intervention group
Group type: COMPARATOR
Intervention: Calcium hydroxylapatite (CaHA) alone
Number of subjects: 50
Study 18076580 — intervention group
Group type: EXPERIMENTAL
Intervention: Ledermix
Number of subjects: 0
Study 18076580 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium hydroxide
Number of subjects: 0
Study 18076580 — intervention group
Group type: COMPARATOR
Intervention: No medication
Number of subjects: 0
Study 15572276 — intervention group
Group type: EXPERIMENTAL
Intervention: Risperidone (4.2±1.7 mg/day)
Number of subjects: 438
Study 15572276 — intervention group
Group type: EXPERIMENTAL
Intervention: Haloperidol (8.0±3.6 mg/day)
Number of subjects: 438
Study 15572276 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 438
Study 15572276 — intervention group
Group type: EXPERIMENTAL
Intervention: Risperidone and Haloperidol (4.1±1.8 mg/day and 7.4±3.7 mg/day respectively) during the subsequent 9 weeks
Number of subjects: 438
Study 15572276 — intervention group
Group type: EXPERIMENTAL
Intervention: Risperidone
Number of subjects: 438
Study 15572276 — intervention group
Group type: EXPERIMENTAL
Intervention: Haloperidol
Number of subjects: 438
Study 12540319 — intervention group
Group type: EXPERIMENTAL
Intervention: Nortriptyline (Pamelor) with weekly behavioral therapy
Number of subjects: 0
Study 12540319 — intervention group
Group type: COMPARATOR
Intervention: Bupropion
Number of subjects: 0
Study 9703790 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium selenite in combination with physical therapy for 3 weeks
Number of subjects: 60
Study 9703790 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 7600143 — intervention group
Group type: EXPERIMENTAL
Intervention: Ebrotidine 800 mg
Number of subjects: 298
Study 7600143 — intervention group
Group type: COMPARATOR
Intervention: Ranitidine 300 mg
Number of subjects: 298
Study 2192562 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive group psychotherapy plus imipramine or placebo
Number of subjects: 68
Study 2192562 — intervention group
Group type: COMPARATOR
Intervention: Imipramine maintenance
Number of subjects: 68
Study 2192562 — intervention group
Group type: COMPARATOR
Intervention: Attendance at maintenance group sessions
Number of subjects: 68
Study 30779530 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent pneumatic compression (median of 22 hours daily for a median of 7 days)
Number of subjects: 2003
Study 30779530 — intervention group
Group type: COMPARATOR
Intervention: Pharmacologic thromboprophylaxis alone (control group)
Number of subjects: 2003
Study 30779530 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent pneumatic compression
Number of subjects: 2003
Study 28877512 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxytocin (OXT)
Number of subjects: 86
Study 28877512 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 86
Study 26181910 — intervention group
Group type: EXPERIMENTAL
Intervention: High-intensity rehabilitation programme with cognitive behavioural therapy
Number of subjects: 54
Study 26181910 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 54
Study 23642951 — intervention group
Group type: EXPERIMENTAL
Intervention: True Individualised Western Herbal Medicine (IWHM) tinctures
Number of subjects: 0
Study 23642951 — intervention group
Group type: COMPARATOR
Intervention: Placebo Individualised Western Herbal Medicine (IWHM) tinctures
Number of subjects: 0
Study 23642951 — intervention group
Group type: COMPARATOR
Intervention: Placebo IWHM
Number of subjects: 0
Study 23642951 — intervention group
Group type: EXPERIMENTAL
Intervention: True IWHM
Number of subjects: 0
Study 21286495 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol (vodka tonic targeting 0.05g% concentration) at 0400 with high homeostatic load (12.25 hrs awake)
Number of subjects: 26
Study 21286495 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol (vodka tonic targeting 0.05g% concentration) at 1600 with medium homeostatic load (8.25 hrs awake)
Number of subjects: 26
Study 21286495 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol (vodka tonic targeting 0.05g% concentration) at 1000 with medium homeostatic load (6.25 hrs awake)
Number of subjects: 26
Study 21286495 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol (vodka tonic targeting 0.05g% concentration) at 2200 with high homeostatic load (10.25 hrs awake)
Number of subjects: 26
Study 21286495 — intervention group
Group type: COMPARATOR
Intervention: Placebo at various times of day
Number of subjects: 26
Study 19187523 — intervention group
Group type: EXPERIMENTAL
Intervention: HSV suppressive therapy
Number of subjects: 0
Study 19187523 — intervention group
Group type: EXPERIMENTAL
Intervention: Repeated post-randomisation measurements
Number of subjects: 0
Study 19187523 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-randomisation measurements of plasma HIV-1 RNA
Number of subjects: 0
Study 19187523 — intervention group
Group type: EXPERIMENTAL
Intervention: Repeated post-randomisation measurements of plasma HIV-1 RNA
Number of subjects: 0
Study 16898386 — intervention group
Group type: COMPARATOR
Intervention: TTT
Number of subjects: 21
Study 16898386 — intervention group
Group type: EXPERIMENTAL
Intervention: TTT+
Number of subjects: 21
Study 15069846 — intervention group
Group type: EXPERIMENTAL
Intervention: Interactive multimedia learning tool
Number of subjects: 0
Study 15069846 — intervention group
Group type: COMPARATOR
Intervention: Text only, text and images, multimedia learning explanations
Number of subjects: 0
Study 11315821 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin glargine (HOE 901) once daily (n = 259)
Number of subjects: 518
Study 11315821 — intervention group
Group type: COMPARATOR
Intervention: NPH insulin once or twice daily (n = 259)
Number of subjects: 518
Study 11315821 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin glargine (HOE 901) once daily
Number of subjects: 518
Study 11315821 — intervention group
Group type: COMPARATOR
Intervention: NPH insulin once or twice daily
Number of subjects: 518
Study 9220540 — intervention group
Group type: EXPERIMENTAL
Intervention: IA-2 beta
Number of subjects: 76
Study 9220540 — intervention group
Group type: EXPERIMENTAL
Intervention: IA-2
Number of subjects: 76
Study 9220540 — intervention group
Group type: EXPERIMENTAL
Intervention: GAD65
Number of subjects: 76
Study 9220540 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of IA-2 beta and IA-2
Number of subjects: 76
Study 9220540 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of IA-2 beta and GAD65
Number of subjects: 76
Study 9220540 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of IA-2 and GAD65
Number of subjects: 76
Study 9220540 — intervention group
Group type: EXPERIMENTAL
Intervention: Blocking with recombinant IA-2, IA-2 beta, or GAD65
Number of subjects: 76
Study 8189572 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic pelvic lymph node dissection followed by radical perineal prostatectomy (group 1)
Number of subjects: 76
Study 8189572 — intervention group
Group type: COMPARATOR
Intervention: Laparoscopic pelvic lymph node dissection and radical retropubic prostatectomy (group 2)
Number of subjects: 76
Study 8189572 — intervention group
Group type: COMPARATOR
Intervention: Standard open lymphadenectomy and radical retropubic prostatectomy (group 3)
Number of subjects: 76
Study 3400843 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal cocaine alone
Number of subjects: 0
Study 3400843 — intervention group
Group type: COMPARATOR
Intervention: Intranasal cocaine with adrenaline 1:1000
Number of subjects: 0
Study 3400843 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 0
Study 31383449 — intervention group
Group type: EXPERIMENTAL
Intervention: Anapanasati meditation (daily for 6 months)
Number of subjects: 90
Study 31383449 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 90
Study 28373411 — intervention group
Group type: EXPERIMENTAL
Intervention: Intense interval training (IIT, n=8)
Number of subjects: 15
Study 28373411 — intervention group
Group type: COMPARATOR
Intervention: No exercise control (n=7)
Number of subjects: 15
Study 26226227 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin (2-mg bovine insulin/kg body mass)
Number of subjects: 15
Study 26226227 — intervention group
Group type: EXPERIMENTAL
Intervention: Oleate (OL) (300 μg/kg)
Number of subjects: 15
Study 26226227 — intervention group
Group type: EXPERIMENTAL
Intervention: Octanoate (OCT) (300 μg/kg)
Number of subjects: 15
Study 26226227 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin + Oleate
Number of subjects: 15
Study 26226227 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin + Octanoate
Number of subjects: 15
Study 26226227 — intervention group
Group type: COMPARATOR
Intervention: Control (saline solution alone)
Number of subjects: 15
Study 24471325 — intervention group
Group type: EXPERIMENTAL
Intervention: New allergic skin test instrument group
Number of subjects: 300
Study 24471325 — intervention group
Group type: COMPARATOR
Intervention: Normal allergic skin test instrument group
Number of subjects: 300
Study 24471325 — intervention group
Group type: COMPARATOR
Intervention: Traditional skin test group
Number of subjects: 300
Study 21807930 — intervention group
Group type: EXPERIMENTAL
Intervention: HMB/ARG/LYS (n = 40)
Number of subjects: 77
Study 21807930 — intervention group
Group type: COMPARATOR
Intervention: Control (isonitrogenous, n = 37)
Number of subjects: 77
Study 21807930 — intervention group
Group type: EXPERIMENTAL
Intervention: HMB/ARG/LYS (n = 40) with vitamin D status <30 ng 25OH-vitD(3)/mL
Number of subjects: 77
Study 18507269 — intervention group
Group type: EXPERIMENTAL
Intervention: Community‐based care (CBC)
Number of subjects: 307
Study 18507269 — intervention group
Group type: COMPARATOR
Intervention: Enhanced usual care (EUC)
Number of subjects: 307
Study 17135039 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclical hormone replacement therapy (HRT) with conjugated equine estrogens (CEE) plus medroxyprogesterone acetate (MPA) for 1 year
Number of subjects: 9
Study 17135039 — intervention group
Group type: EXPERIMENTAL
Intervention: 17beta-estradiol gel with the same schedule of MPA administration for 1 year
Number of subjects: 9
Study 14561977 — intervention group
Group type: EXPERIMENTAL
Intervention: Linezolid
Number of subjects: 22
Study 11116776 — intervention group
Group type: EXPERIMENTAL
Intervention: Emotionally charged story (arousing story)
Number of subjects: 44
Study 11116776 — intervention group
Group type: COMPARATOR
Intervention: Neutral story
Number of subjects: 44
Study 9219145 — intervention group
Group type: EXPERIMENTAL
Intervention: Methamphetamine abuse
Number of subjects: 16
Study 9219145 — intervention group
Group type: EXPERIMENTAL
Intervention: Drug use before or during sex
Number of subjects: 16
Study 1451715 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin
Number of subjects: 36
Study 1451715 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study 6198057 — intervention group
Group type: EXPERIMENTAL
Intervention: Prioderm lotion (0.5% malathion in isopropanol)
Number of subjects: 62